Old dog, new trick: Maruho gains Japan rights to Pierre Fabre's hemangioma drug
This article was originally published in Scrip
Propranolol may be the result of an earlier, simpler age of drug discovery in the 1960s but there is still life left in the aging beta-blocker yet, as shown by Laboratoires Pierre Fabre's new Japanese licensing deal for the product.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.